Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors

Hepatology Research

Volumn 46, Issue 10, 2016, Pages 1011-1018

  Honda, Yasushi ^a   Yoneda, Masato ^a   Kessoku, Takaomi ^a   Ogawa, Yuji ^a   Tomeno, Wataru ^a   Imajo, Kento ^a   Mawatari, Hironori ^a   Fujita, Koji ^a   Hyogo, Hideyuki ^b   Ueno, Takato ^c   Chayama, Kazuaki ^d   Saito, Satoru ^a   Nakajima, Atsushi ^a   Hotta, Kikuko ^e  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JA Hiroshima General Hospital   (Japan)

^c KURUME UNIVERSITY   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

non alcoholic fatty liver disease; non obese non alcoholic fatty liver disease; PNPLA3; type 2 diabetes mellitus

Indexed keywords

ADULT; AGE; ARTICLE; BODY MASS; CELL SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEPATITIS; HUMAN; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PNPLA3 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84985994897     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12648     Document Type: Article

References (47)

1. Angulo P. Nonalcoholic fatty liver disease. New Engl J Med 2002; 346: 1221–31.
2. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia–Pacific region? J Gastroenterol Hepatol 2003; 18: 124–38.
3. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23.
4. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202–19.
5. S-i K, Watanabe N, Numata M et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954–61.
6. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679–89.
7. Dunn W, Schwimmer J. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 2008; 10: 67–72.
8. Crespo J, Fernández-Gil P, Hernández-Guerra M et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg 2001; 11: 254–7.
9. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
10. Beymer C, Kowdley KV, Larson A et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003; 138: 1240–4.
11. Gholam P, Kotler D, Flancbaum L. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 2002; 12: 49–51.
12. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.
13. Assy N, Kaita K, Mymin D et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929–34.
14. Namikawa C, Shu-Ping Z, Vyselaar JR et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004; 40: 781–6.
15. Gambino R, Cassader M, Pagano G et al. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 2007; 45: 1097–107.
16. Tokushige K, Takakura M, Tsuchiya-Matsushita N et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 2007; 46: 1104–10.
17. de Alwis N, Day C. Genes and nonalcoholic fatty liver disease. Curr Diab Rep 2008; 8: 156–63.
18. Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol 2012; 35: 32–41.
19. Chalasani N, Guo X, Loomba R et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 1567–76, 1576 e1561–1566.
20. Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
21. Kawaguchi T, Sumida Y, Umemura A et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012; 7: e38322.
22. Yuan X, Waterworth D, Perry JRB et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520–8.
23. Hotta K, Yoneda M, Hyogo H et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010; 11: 172.
24. Kitamoto T, Kitamoto A, Yoneda M et al. Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. J Hum Genet 2014; 59: 241–6.
25. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883–94.
26. Omagari K, Kadokawa Y, Masuda J-I et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1098–105.
27. Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586–95.
28. Kim H, Kim H, Lee K et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169–75.
29. Das K, Das K, Mukherjee PS et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593–602.
30. Vendhan R, Amutha A, Anjana RM et al. Comparison of characteristics between nonobese and overweight/obese subjects with nonalcoholic fatty liver disease in a South Indian population. Diabetes Technol Ther 2014; 16: 48–55.
31. Kitamoto T, Kitamoto A, Yoneda M et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013; 132: 783–92.
32. Kitamoto A, Kitamoto T, Nakamura T et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocrine J 2014; 61: 683–9.
33. Force. IOT. International Obesity Task Force. The Asian-Pacific perspective: redefining obesity and its treatment. Health Communications Australia Pty Limited; 2000.
34. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes M, Seino Y, Nanjo K, Tajima N et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010;1:212-228.
35. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
36. Brunt EM, Janney CG, Di Bisceglie AM et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–74.
37. Xu C, Yu C, Ma H et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 2013; 108: 1299–304.
38. Kim NH, Kim JH, Kim YJ et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int 2014; 34: 604–11.
39. Nishioji K, Sumida Y, Kamaguchi M et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol 2015; 50: 95–108.
40. Oniki K, Saruwatari J, Izuka T, Kajiwara A et al. Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects. PLoS One 2015; 10: e0132640.
41. Nishioji K, Mochizuki N, Kobayashi M et al. The Impact of PNPLA3 rs738409 Genetic Polymorphism and Weight Gain ≥10 kg after Age 20 on Non-Alcoholic Fatty Liver Disease in Non-Obese Japanese Individuals. PLoS One 2015; 10: e0140427.
42. Hernaez R, McLean J, Lazo M et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the Third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 2013; 11: 1183–90.e1182.
43. Shen J, Wong GL, Chan HL et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014; 39: 532–9.
44. Kitamoto T, Kitamoto A, Ogawa Y et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol 2015; 63: 494–502.
45. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883–94.
46. Kollerits B, Coassin S, Beckmann ND et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genetics 2009; 18: 4669–76.
47. Speliotes EK, Butler JL, Palmer CD et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52: 904–12.